Strict Competition Policy Is Not A Barrier To Bigger Firms

The European Commission is under immense pressure to relax antitrust enforcement to foster “continental champions” capable of rivaling US and Chinese giants. However, weakening merger controls risks creating inefficient monopolies rather than innovative leaders, potentially stifling the very competitiveness Brussels seeks to ignite. The fiscal reality suggests that capital allocation efficiency, not just corporate size, determines market viability.

Brussels is flirting with a dangerous idea. The narrative circulating through the corridors of the Berlaymont is seductive in its simplicity: Europe lacks scale, therefore Europe must merge. Proponents argue that strict competition policy acts as a brake on growth, preventing local firms from achieving the critical mass necessary to compete globally. But this logic ignores a fundamental tenet of corporate finance. Size does not equal strength. In many cases, unchecked consolidation creates bloated balance sheets laden with goodwill impairments and stagnant cash flows.

The catalyst for this regulatory shift is the lingering shadow of the Draghi Report, which highlighted Europe’s widening productivity gap with the United States. Even as the diagnosis of underinvestment is accurate, the prescription of deregulated M&A is suspect. When regulators lower the bar for approval, they invite a wave of defensive consolidation. Companies merge not to innovate, but to cut costs and eliminate competition. This is financial engineering, not industrial strategy.

Consider the data. Historical analysis of mega-mergers in the telecom and banking sectors across the Eurozone reveals a troubling pattern. Post-merger integration often destroys shareholder value in the medium term. According to data from the European Central Bank, sectors with high concentration ratios in Europe have shown slower productivity growth over the last decade compared to more fragmented, competitive markets. The “quiet life” hypothesis holds true: managers in less competitive environments tend to innovate less.

Institutional capital is watching this debate closely. The market does not reward bloat; it rewards return on invested capital (ROIC). If European firms apply lax rules to acquire competitors rather than invest in R&D, the multiple compression will be severe. We are already seeing skepticism from the buy-side regarding deals that lack clear synergies beyond revenue stacking.

“We are not seeing a lack of scale as the primary bottleneck for European tech; we are seeing a lack of risk capital. Merging two mediocre companies does not create a great one. It creates a large, inefficient one.” — Elena Rossi, Chief Investment Officer, Alpine Capital Partners

The push for weaker rules creates immediate friction for corporate strategy departments. Navigating a shifting regulatory landscape requires precise legal foresight. Companies attempting to capitalize on potential deregulation must engage with top-tier antitrust and competition law firms to stress-test deals against both current and future enforcement standards. A deal approved today under relaxed rules could face retroactive scrutiny or reputational damage if the political wind shifts in the next election cycle.

The Three Structural Risks of Deregulation

If the Commission proceeds with softening its merger guidelines, three specific macroeconomic risks emerge that every CFO and board member must model into their long-term forecasts.

• Innovation Stagnation: Reduced competitive pressure lowers the imperative for R&D spend. In the pharmaceutical and deep-tech sectors, where Europe holds significant potential, monopoly power often leads to patent evergreening rather than breakthrough discovery. The marginal utility of capital drops when dominance is guaranteed by regulation rather than merit.
• Input Cost Inflation: Consolidation in supply chain critical sectors—such as energy, logistics and raw materials—gives dominant players pricing power. This passes directly through to the P&L of downstream manufacturers, compressing EBITDA margins across the industrial base. We saw this dynamic play out in the post-pandemic shipping consolidation; the lesson was expensive.
• Regulatory Arbitrage: A fragmented approach to merger control within the EU creates loopholes. If the central authority weakens while national regulators remain strict, it creates a complex web of compliance hurdles. Multinationals will necessitate to retain specialized regulatory compliance consultants to navigate the dissonance between Brussels and member states like Germany or France, increasing the cost of doing business.

The solution to Europe’s competitiveness crisis lies deeper than merger policy. It requires a functioning Capital Markets Union to unlock the private equity and venture capital trapped on national balance sheets. The US dominates given that its capital markets are deep, liquid, and willing to fund high-risk innovation. Europe’s banks remain too risk-averse, and its equity markets too fragmented.

For the private sector, the immediate implication is volatility. Strategic planners cannot rely on a “buy your way to growth” strategy if the regulatory environment remains unpredictable. The smart money is shifting focus toward organic growth and bolt-on acquisitions that offer genuine technological synergies. This requires rigorous due diligence. Firms are increasingly turning to M&A advisory and valuation specialists to identify targets that offer genuine IP value rather than just market share.

The Verdict on Market Concentration

We must look at the yield curve of innovation. In sectors where Europe leads, such as luxury goods and specialized machinery, competition remains fierce among mid-cap players. This friction drives quality. Diluting antitrust enforcement threatens to homogenize these sectors, turning unique value propositions into commoditized offerings.

The European Commission should reckon twice, not out of ideological rigidity, but out of fiscal prudence. Weakening merger rules is a short-term fix for a long-term structural problem. It treats the symptom (small companies) while ignoring the disease (lack of risk capital and fragmented markets). For investors and corporate leaders, the signal is clear: do not bet on regulatory arbitrage. Bet on efficiency. Bet on innovation. And ensure your advisory bench is strong enough to navigate whatever policy U-turns Brussels decides to make next.

The market will ultimately punish inefficiency, regardless of what the regulators allow. The question for European business leaders is whether they will build companies that survive on merit or those that survive on permission. The former builds legacy; the latter builds liability.